About Glucoside xylosyltransferase 1
Glucoside xylosyltransferase 1 (GXYLT1) is a protein
from Homo sapiens identified by UniProt accession
Q4G148, 440 residues long.
MolForge cross-references it against 0 known binders and
63 disease associations.
Target properties
| Protein name | Glucoside xylosyltransferase 1 |
| UniProt accession | Q4G148 |
| Gene | GXYLT1 |
| Organism | Homo sapiens |
| Length | 440 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (63)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.26
- HbA1c measurement · score 0.23
- response to sulfonylurea · score 0.23
- refractive error · score 0.20
- blood urea nitrogen measurement · score 0.15
- Brugada syndrome · score 0.08
- familial atrial fibrillation · score 0.07
- Familial progressive cardiac conduction defect · score 0.07
- atrioventricular dissociation · score 0.07
- familial sick sinus syndrome · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q4G148-F1 | alphafold | PREDICTED | 83.81 | — |
Amino-acid sequence (440 residues)
MRRYLRVVVL CVACGFCSLL YAFSQLAVSL EEGTGGGGGK PQAAVASWLA GGGRGAVRGA GVAGPAAHPG VSDRCKDFSL CYWNPYWMLP SDVCGMNCFW EAAFRYSLKI QPVEKMHLAV VACGERLEET MTMLKSAIIF SIKPLQFHIF AEDQLHHSFK GRLDNWSFLQ TFNYTLYPIT FPSENAAEWK KLFKPCASQR LFLPLILKEV DSLLYVDTDI LFLRPVDDIW SLLKKFNSTQ IAAMAPEHEE PRIGWYNRFA RHPYYGKTGV NSGVMLMNMT RMRRKYFKND MTTVRLQWGD ILMPLLKKYK LNITWGDQDL LNIVFFHNPE SLFVFPCQWN YRPDHCIYGS NCQEAEEGGI FILHGNRGVY HDDKQPAFRA VYEALRNCSF EDDNIRSLLK PLELELQKTV HTYCGKIYKI FIKQLAKSVR DRYARSPKEK
Explore Glucoside xylosyltransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets